481 related articles for article (PubMed ID: 33991479)
21. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
Duffy SW; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith RA; Evans A; Blyuss O; Johns L; Ellis IO; Myles J; Sasieni PD; Moss SM
Lancet Oncol; 2020 Sep; 21(9):1165-1172. PubMed ID: 32800099
[TBL] [Abstract][Full Text] [Related]
22. Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Dilley J; Burnell M; Gentry-Maharaj A; Ryan A; Neophytou C; Apostolidou S; Karpinskyj C; Kalsi J; Mould T; Woolas R; Singh N; Widschwendter M; Fallowfield L; Campbell S; Skates SJ; McGuire A; Parmar M; Jacobs I; Menon U
Gynecol Oncol; 2020 Aug; 158(2):316-322. PubMed ID: 32561125
[TBL] [Abstract][Full Text] [Related]
23. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
Menon U; Ryan A; Kalsi J; Gentry-Maharaj A; Dawnay A; Habib M; Apostolidou S; Singh N; Benjamin E; Burnell M; Davies S; Sharma A; Gunu R; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Seif MW; Jenkins H; Mould T; Woolas R; Murdoch JB; Dobbs S; Amso NN; Leeson S; Cruickshank D; Scott I; Fallowfield L; Widschwendter M; Reynolds K; McGuire A; Campbell S; Parmar M; Skates SJ; Jacobs I
J Clin Oncol; 2015 Jun; 33(18):2062-71. PubMed ID: 25964255
[TBL] [Abstract][Full Text] [Related]
24. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Henderson JT; Webber EM; Sawaya GF
JAMA; 2018 Feb; 319(6):595-606. PubMed ID: 29450530
[TBL] [Abstract][Full Text] [Related]
25. Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Sharma A; Burnell M; Gentry-Maharaj A; Campbell S; Amso NN; Seif MW; Fletcher G; Brunel C; Turner G; Rangar R; Ryan A; Jacobs I; Menon U;
Ultrasound Obstet Gynecol; 2013 Oct; 42(4):472-7. PubMed ID: 23456790
[TBL] [Abstract][Full Text] [Related]
26. The role of transvaginal ultrasound in screening for ovarian cancer.
Campbell S; Gentry-Maharaj A
Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
[TBL] [Abstract][Full Text] [Related]
27. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.
Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; Mariño IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U
Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833
[No Abstract] [Full Text] [Related]
29. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
30. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial.
Moss SM; Wale C; Smith R; Evans A; Cuckle H; Duffy SW
Lancet Oncol; 2015 Sep; 16(9):1123-1132. PubMed ID: 26206144
[TBL] [Abstract][Full Text] [Related]
31. Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Kalsi J; Gentry-Maharaj A; Ryan A; Singh N; Burnell M; Massingham S; Apostolidou S; Sharma A; Williamson K; Seif M; Mould T; Woolas R; Dobbs S; Leeson S; Fallowfield L; Skates SJ; Parmar M; Campbell S; Jacobs I; McGuire A; Menon U
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670571
[TBL] [Abstract][Full Text] [Related]
32. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Buys SS; Partridge E; Black A; Johnson CC; Lamerato L; Isaacs C; Reding DJ; Greenlee RT; Yokochi LA; Kessel B; Crawford ED; Church TR; Andriole GL; Weissfeld JL; Fouad MN; Chia D; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hartge P; Pinsky PF; Zhu CS; Izmirlian G; Kramer BS; Miller AB; Xu JL; Prorok PC; Gohagan JK; Berg CD;
JAMA; 2011 Jun; 305(22):2295-303. PubMed ID: 21642681
[TBL] [Abstract][Full Text] [Related]
33. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial.
Atkin W; Wooldrage K; Parkin DM; Kralj-Hans I; MacRae E; Shah U; Duffy S; Cross AJ
Lancet; 2017 Apr; 389(10076):1299-1311. PubMed ID: 28236467
[TBL] [Abstract][Full Text] [Related]
34. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Gallardo-Rincon D; Blagden S; Brenton J; Perren TJ; Sundar S; Lord R; Dark G; Hall M; Banerjee S; Glasspool RM; Hanna CL; Williams S; Scatchard KM; Nam H; Essapen S; Parkinson C; McAvan L; Swart AM; Popoola B; Schiavone F; Badrock J; Fananapazir F; Cook AD; Parmar M; Kaplan R; Ledermann JA
Lancet Oncol; 2022 Jul; 23(7):919-930. PubMed ID: 35690073
[TBL] [Abstract][Full Text] [Related]
35. Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study.
Sharma A; Gentry-Maharaj A; Burnell M; Fourkala EO; Campbell S; Amso N; Seif MW; Ryan A; Parmar M; Jacobs I; Menon U;
BJOG; 2012 Jan; 119(2):207-19. PubMed ID: 21762355
[TBL] [Abstract][Full Text] [Related]
36. Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study.
Menon U; Gentry-Maharaj A; Ryan A; Sharma A; Burnell M; Hallett R; Lewis S; Lopez A; Godfrey K; Oram D; Herod J; Williamson K; Seif M; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso N; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Skates S; Parmar M; Jacobs I
BMJ; 2008 Nov; 337():a2079. PubMed ID: 19008269
[TBL] [Abstract][Full Text] [Related]
37. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
Blagden SP; Cook AD; Poole C; Howells L; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; James EC; White IR; Perren T; Lord R; Dark G; Earl HM; Hall M; Kaplan R; Ledermann JA; Clamp AR
Lancet Oncol; 2020 Jul; 21(7):969-977. PubMed ID: 32615110
[TBL] [Abstract][Full Text] [Related]
38. Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening.
Burnell M; Gentry-Maharaj A; Glazer C; Karpinskyj C; Ryan A; Apostolidou S; Kalsi J; Parmar M; Campbell S; Jacobs I; Menon U
Ultrasound Obstet Gynecol; 2020 Aug; 56(2):267-275. PubMed ID: 31614036
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
